Significance of KEYNOTE-045 Trial of Pembrolizumab vs Chemotherapy in Urothelial Carcinoma
June 22nd 2017Daniel P. Petrylak, MD, professor of Medicine and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the KEYNOTE-045 trial, a phase III open-label study of pembrolizumab (Keytruda) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial carcinoma.
Watch
Results for First-Line Pembrolizumab in Advanced Urothelial Carcinoma
June 21st 2017Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.
Watch
First-Line Carboplatin and Pemetrexed With Pembrolizumab for NSCLC
June 21st 2017Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses first-line carboplatin and pemetrexed with or without pembrolizumab for advanced nonsquamous non–small cell lung cancer.
Watch
Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC
June 20th 2017Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.
Watch
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC
June 19th 2017Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.
Watch
Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain Metastases
June 19th 2017Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses the activity seen with the combination of dabrafenib and trametinib for the treatment of patients with melanoma brain metastases.
Watch
The Complexity of the PARP Inhibitor Landscape in Ovarian Cancer
June 16th 2017Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.
Watch
Comprehensive Genomic Profiling With Loss of Heterozygosity for Ovarian Cancer Treatment
June 16th 2017Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study of comprehensive genomic profiling with loss of heterozygosity to identify therapeutically relevant subsets of ovarian cancer.
Watch
The Potential of Ibrutinib Combinations for the Treatment of CLL
June 16th 2017Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.
Watch
Association Between Gut Microbiome and Responses in Melanoma Patients on Anti-PD-1 Therapy
June 15th 2017Jennifer Wargo, MD, associate professor of Genomic Medicine and Surgical Oncology, discusses a study that looked at the association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy.
Watch
Andrzej Jakubowiak, MD, PhD, professor of Medicine, University of Chicago Medicine, discusses safety results from an open label, phase 1b trial exploring daratumumab (Darzalex) combined with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma.
Watch
Promising Results for Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Pancreatic Cancer
June 14th 2017Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses results of the CanStem111P trial, a phase III study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma.
Watch
Efficacy and Safety Results for Pembrolizumab in Previously Treated Gastric Cancer
June 13th 2017Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses efficacy and safety results for pembrolizumab (Keytruda) monotherapy in patients with previously treated advanced gastric cancer.
Watch
How Care for Merkel Cell Carcinoma Has Been Revolutionized in Recent Years
June 13th 2017Ragini R. Kudchadkar, MD, assistant professor, department of Hematology and Medical Oncology, Emory University School of Medicine, discusses how care for Merkel cell carcinoma has been revolutionized in recent years.
Watch